U.S. markets closed

MusclePharm Corporation (MSLP)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4310+0.0310 (+7.75%)
At close: 01:46PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4000
BidN/A x N/A
AskN/A x N/A
Day's Range0.3755 - 0.4310
52 Week Range0.1200 - 3.0000
Avg. Volume17,093
Market Cap14.389M
Beta (5Y Monthly)0.29
PE Ratio (TTM)N/A
EPS (TTM)-0.0990
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for MSLP

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Fair Value
    Economic Moat
    3 months agoMorningstar
View more
  • GlobeNewswire

    MusclePharm Announces Third Quarter 2021 Financial Results

    Company Continues Focus on Controlling Operating Expenses with 21% Decline in Third Quarter 2021 First Production Run of MP Combat Energy Successfully Sold 100%; $30 Million of Annual Sales Expected in 2023 Company Expects Sequential Revenue Growth in Fourth Quarter 2021 fromNew Product Formulation and MP Energy Drink Line LAS VEGAS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- MusclePharm Corporation (OTCMKTS: MSLP), a global provider of leading sports nutrition & lifestyle branded nutritional supplements

  • GlobeNewswire

    MusclePharm to Announce Third Quarter 2021 Financial Results on Monday, November 15, 2021

    CALABASAS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- MusclePharm Corporation (OTCMKTS: MSLP), a global provider of leading sports nutrition and lifestyle branded nutritional supplements, announced today that the Company will report its financial results for the third quarter ended September 30, 2021, after the market closes on Monday, November 15, 2021. The Company will host a conference call to discuss its operating results on Monday, November 15, 2021, at 1:30 pm Pacific Time (4:30 pm Eastern

  • GlobeNewswire

    MusclePharm adds former Rockstar Energy executive to MP beverage team to lead product development and marketing for two new Performance Energy drinks

    CALABASAS, Calif., Oct. 29, 2021 (GLOBE NEWSWIRE) -- MusclePharm Corporation (OTCMKTS: MSLP), a global provider of leading sports nutrition and lifestyle branded nutritional supplements, today announced a partnership with former Rockstar Energy executive, Jason May. Mr. May will join the MP beverage team currently headed up by Joey Cannata, another long time Rockstar Energy veteran. The MP beverage team will be launching two fully functional energy drink lines, MP Combat Energy and FitMiss Energ